RizaCare infusion, manufactured by Novartis Pharma, contains L-lysine hydrochloride and L-arginine hydrochloride, available as a 1L 1 bag injectable drug (YJ code: 3253416A1020). This solution is indicated for the reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
RizaCare infusion
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →